Skip to main content
1-800-833-0680NET 30 Available

Resources & Guides

In-depth guides for clinicians, HR professionals, and program directors who use drug screening day-to-day.

In-depth guides

Reviewed clinical references with agency-sourced citations.

Detection

How long do drugs stay in your system?

A specimen-by-specimen reference for the most commonly tested substances, with the clinical and pharmacokinetic factors that move the windows.

Read guide →

Workplace

Drug testing in the workplace

A practical reference for HR and compliance teams on why employers test, what the federal framework requires, and how to choose a defensible panel and matrix.

Read guide →

reference

How drug tests work

A technical primer on lateral-flow immunoassay chemistry, cutoffs, confirmation testing, specimen validity, and the regulatory framework that governs point-of-care drug screening.

Read guide →

substances

What drugs do tests detect?

A panel-by-panel reference covering the SAMHSA-5, expanded 10-panel additions, and modern 12- to 17-panel devices — with detection windows and the Magenta panels that include each analyte.

Read guide →

Detection

How long will marijuana show in a drug test?

A THC-specific clinical reference covering urine, oral fluid, blood, and hair detection windows — and the frequency, dose, body-composition, second-hand-exposure, and CBD-contamination variables that move every published number.

Read guide →

substances

Drug testing for methamphetamine

A clinical reference on the SAMHSA 500/250 cutoff, d-methamphetamine versus l-methamphetamine chiral confirmation, common cross-reactivities, MRO workflow, and program design for corrections, MAT, and other high-prevalence populations.

Read guide →

substances

Fentanyl addiction risks

A clinical reference on why illicit fentanyl drives current overdose mortality, how tolerance and naloxone dosing have shifted, what MOUD options programs should know about, and why every screening panel now needs fentanyl coverage.

Read guide →

substances

How do people encounter fentanyl?

A clinician and HR field reference on the illicit-fentanyl supply: counterfeit pills, contamination of heroin, cocaine, and methamphetamine, why standard opiate panels miss it, and what testing additions a defensible program requires.

Read guide →

substances

Illicit fentanyl on the rise

An operational reference for clinical, workplace, and harm-reduction program administrators tracking the supply-side and epidemiologic shifts that now require fentanyl coverage in every screening panel.

Read guide →

substances

What is fentanyl

A clinical and analytical pharmacology primer on fentanyl, its metabolism, pharmaceutical product landscape, illicit analogs, and the testing requirements that distinguish defensible programs from incomplete ones.

Read guide →

substances

Is medical marijuana safe for testing programs to accept

A program-administrator reference on how state medical-cannabis authorizations interact with federal workplace testing, MRO defenses, hemp-derived isomer cross-contamination, and ADA jurisprudence — written for clinical and HR buyers, not consumers.

Read guide →

substances

Is kratom addictive

A clinical and analytical reference on kratom pharmacology, FDA and CDC surveillance posture, dependence and withdrawal characterization, and why standard opiate immunoassays do not detect mitragynine alkaloids — written for clinical, MAT, and program-administrator buyers.

Read guide →

Compliance

DEA scheduling of kratom

What program administrators need to know about kratom's federal status, FDA import alerts, the state-level scheduling patchwork, and the implications for workplace and clinical drug-testing panels.

Read guide →

substances

Overdose deaths and synthetic opioids

How fentanyl, novel benzimidazoles, and polysubstance combinations have reshaped the U.S. overdose landscape — and what that means for testing-program design.

Read guide →

reference

Drug-testing abbreviations and acronyms

A reference glossary of the analyte codes, testing-program acronyms, regulatory designations, and B2B terms program buyers encounter on cassettes, lab reports, and SAMHSA documentation.

Read guide →